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abstract 
Post-translational modifications of histones play an important role in the regulation of gene 
expression. Enhancer of zeste homologue 2 (EZH2) is a subunit of polycomb repressive 
complex 2 (PRC2) that methylates histone H3 lysine 27 (H3K27) and leads to chromatin 
compaction and gene silencing. Dysregulation of enhancer of EZH2 is found in many 
types of cancers especially in highly progressive and aggressive ones. Specific 
catalytic inhibitors of EZH2 have high anti-tumour activity, particularly in lymphomas 
with EZH2 activating mutations. However, the clinical benefits of EZH2 catalytic 
inhibitors in tumours overexpressing EZH2 are still limited.  
Here, we identified NPD13668, a novel modulator of EZH2-mediated gene 
silencing, from 329,049 small chemical compounds by cell-based high-throughput 
screening assay. NPD13668 reactivated the expression of silenced H3K27me3 
target genes together with depletion of the H3K27me3 modification. In addition, 
NPD13668 repressed the cell growth of prostate cancer cell lines (PC3 and 
LNCaP) and ovarian cancer cell lines (SKOV3 and NIH-OVCAR3). NPD13668 
partially inhibited the methyltransferase activity of EZH2 in vitro. Genome-wide 
expression analysis revealed that after NPD13668 treatment, about half of the 
upregulated genes overlapped with genes upregulated after treatment with 
GSK126, a EZH2 catalytic inhibitor, indicating that NPD13668 is a potential 
modulator of EZH2 methyltransferase activity. Our data demonstrated that targeting 
the pharmacological inhibition of EZH2 activity by NPD13668 might be a novel 
cancer treatment. 
 
